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ABSTRACT
Despite the nutritional and health benefits of breast milk, breast milk can serve as a vector for mother-to-child HIV transmis-
sion. Most HIV-infected infants acquire HIV through breastfeeding. Paradoxically, most infants breastfed by HIV-positive
women do not become infected. This is potentially attributed to anti-HIV factors in breast milk. Breast milk of HIV-negative
women can inhibit HIV infection. However, the HIV-inhibitory activity of breast milk from HIV-positive mothers has not been
evaluated. In addition, while significant differences in breast milk composition between transmitting and nontransmitting HIV-
positive mothers have been correlated with transmission risk, the HIV-inhibitory activity of their breast milk has not been com-
pared. This knowledge may significantly impact the design of prevention approaches in resource-limited settings that do not
deny infants of HIV-positive women the health benefits of breast milk. Here, we utilized bone marrow/liver/thymus humanized
mice to evaluate the in vivo HIV-inhibitory activity of breast milk obtained from HIV-positive transmitting and nontransmit-
ting mothers. We also assessed the species specificity and biochemical characteristics of milk’s in vivo HIV-inhibitory activity
and its ability to inhibit other modes of HIV infection. Our results demonstrate that breast milk of HIV-positive mothers has
potent HIV-inhibitory activity and indicate that breast milk can prevent multiple routes of infection. Most importantly, this ac-
tivity is unique to human milk. Our results also suggest multiple factors in breast milk may contribute to its HIV-inhibitory ac-
tivity. Collectively, our results support current recommendations that HIV-positive mothers in resource-limited settings exclu-
sively breastfeed in combination with antiretroviral therapy.
IMPORTANCE
Approximately 240,000 children become infected with HIV annually, the majority via breastfeeding. Despite daily exposure to
virus in breast milk, most infants breastfed by HIV-positive women do not acquire HIV. The low risk of breastfeeding-associated
HIV transmission is likely due to antiviral factors in breast milk. It is well documented that breast milk of HIV-negative women
can inhibit HIV infection. Here, we demonstrate, for the first time, that breast milk of HIV-positive mothers (nontransmitters
and transmitters) inhibits HIV transmission. We also demonstrate that breast milk can prevent multiple routes of HIV acquisi-
tion and that this activity is unique to human milk. Collectively, our results support current guidelines which recommend that
HIV-positive women in resource-limited settings exclusively breastfeed in combination with infant or maternal antiretroviral
therapy.
Breast milk provides newborn infants with all of their dailynutritional and fluid requirements. It is also a rich source of
hormones, antimicrobial factors, and immune components that
decrease the susceptibility of breastfed infants to infectious dis-
eases (1). For these reasons, the World Health Organization
(WHO) recommends that mothers exclusively breastfeed their
infants for the first 6 months of life (2). However, despite the
nutritional and health benefits of breastfeeding, in some instances,
breast milk can serve as a vector for mother-to-child transmission
of infectious pathogens (3).
Infants born to HIV-positive women can acquire HIV orally by
ingesting their mother’s breast milk which may contain virus par-
ticles (cell-free HIV) and/or virus-infected cells (cell-associated
HIV). An estimated 240,000 children become infected with HIV
annually, mostly via breastfeeding (4). In developed countries,
HIV-positive mothers abstain from breastfeeding and substitute
formula for breast milk. In resource-limited regions, HIV-positive
mothers breastfeed their infants because the health benefits of
breast milk outweigh the risk of HIV transmission. In this setting,
the WHO recommends that HIV-positive mothers exclusively
breastfeed their infants for the first 6 months of life in combina-
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tion with infant or maternal antiretroviral therapy (ART) (5). Al-
though these strategies significantly reduce HIV transmission, the
success of ART relies on adherence, which is limited by cost, ac-
cess, and social factors. It is estimated that only 67% of HIV-
positive pregnant women in low- and middle-income countries
receive ART to prevent mother-to-child transmission (4). There-
fore, novel approaches that effectively prevent breastfeeding HIV
transmission without denying infants the health benefits of breast
milk are urgently needed.
Surprisingly, in the absence of ART, the majority of infants breast-
fed by HIV-positive women do not acquire HIV (85%) despite
ingesting breast milk daily for several months to years (250 liters per
year) (6). Higher levels of alpha-defensins, IL-15, erythropoietin, oli-
gosaccharides, long-chain polyunsaturated fatty acids (LCPUFAs)
and antibody-dependent cell-mediated cytotoxicity in breast milk
have been correlated with a decreased risk of breastfeeding HIV trans-
mission (7–12). Breast milk also contains several factors that inhibit
HIV infection in vitro (13–22). For example, Fouda et al. recently
demonstrated that tenascin-C (TNC), a novel high-molecular-
weight protein in breast milk, can inhibit HIV infection in vitro by
capturing and binding to HIV virions via the chemokine coreceptor
binding site on the HIV envelope protein (23). While these observa-
tions suggested that breast milk limits HIV transmission, until re-
cently it was difficult to directly assess the effect of breast milk on oral
HIV transmission. In vivo HIV studies are severely limited by the
strict species tropism of the virus.
For this purpose, we developed a novel humanized mouse
model of oral HIV transmission utilizing bone marrow/liver/thy-
mus (BLT) humanized mice. We demonstrated that systemic re-
constitution of BLT mice with human hematopoietic cells renders
them susceptible to oral HIV transmission. Oral HIV transmis-
sion in BLT mice results in the presence of virus in plasma and
saliva, virus dissemination, and systemic CD4 T cell depletion,
recapitulating the human condition (24). We then used BLT mice
to demonstrate that whole breast milk obtained from HIV-nega-
tive women can prevent oral HIV transmission (24). The in vivo
HIV-inhibitory activity of breast milk observed is due to intrinsic
antiviral factors as the breast milk of HIV-negative women does
not contain any kind of HIV-specific antibodies or immune cells.
Although we demonstrated a protective effect of breast milk on
oral HIV transmission, it remained unknown whether the breast
milk of HIV-positive women could inhibit HIV infection in vivo.
In addition, while significant differences in breast milk composi-
tion have been correlated with transmission risk, the HIV-inhib-
itory activity of breast milk obtained from transmitting and
nontransmitting HIV-positive mothers had not been directly
compared. This knowledge could have significant implications in
regard to the design of novel approaches to prevent HIV transmis-
sion through breastfeeding. Therefore, we evaluated the in vivo
HIV-inhibitory activity of breast milk obtained from HIV-posi-
tive transmitting and nontransmitting mothers. Our results dem-
onstrate that the breast milk of HIV-positive transmitting and
nontransmitting mothers can inhibit HIV infection in vivo. Next,
we assessed the specificity of breast milk’s in vivo HIV-inhibitory
activity and its ability to provide sterilizing protection from HIV
acquisition to gain a better understanding of the factors in breast
milk that inhibit HIV infection in vivo. First, we established that
the HIV-inhibitory activity of milk is restricted to humans. Next,
we characterized properties of breast milk’s in vivo HIV-inhibi-
tory activity. Finally, we demonstrated that human breast milk
contains natural and potent inhibitors that efficiently inhibit vag-
inal HIV transmission and provide sterilizing protection from an
intravenous HIV exposure.
MATERIALS AND METHODS
Generation of humanized BLT mice. Humanized BLT mice were gener-
ated as previously described by transplanting human liver-derived
CD34 hematopoietic stem cells intravenously into 6- to 8-week old
NOD.Cg-Prkdcscid ll2rgtm1Wjl/SzJ (NSG; The Jackson Laboratory, Bar
Harbor, ME) or NOD.Cg-Prkdcscid ll2rgtm1Wjl Tg(HLA-A2.1)1Enge/SzJ
(NSG-A2; The Jackson Laboratory, Bar Harbor, ME) mice previously
implanted (under the kidney capsule) with a piece of autologous human
liver sandwiched between two pieces of human thymus (Advanced Bio-
science Resources, Alameda, CA) (25–27). Systemic reconstitution with
human immune cells was monitored in peripheral blood (PB) by flow
cytometry, as we previously described (25–27). Mice were maintained
under specific-pathogen-free conditions by the Division of Laboratory
Animal Medicine according to protocols approved by the Institutional
Animal Care and Use Committee at the University of North Carolina–
Chapel Hill.
HIV exposure of humanized BLT mice. Stocks of HIV-1JR-CSF were
prepared and titers were determined on TZM-bl cells as previously de-
scribed (25, 26) to calculate the number of tissue culture infectious units
(TCIU) per ml. Oral HIV exposures were performed as previously de-
scribed (24). Briefly, anesthetized BLT mice were exposed orally to HIV by
distilling virus (1.4  106 to 1.8  106 TCIU) resuspended in 20 l of
vehicle (RPMI medium or phosphate-buffered saline [PBS]), vehicle sup-
plemented with human milk oligosaccharides, tenascin-C, or lactoferrin
(AbD Serotec, Kidlington, United Kingdom) or milk (human, cow, goat,
camel, rhesus macaques, and African green monkeys) directly into the
oral cavity. Vaginal exposures were also performed essentially as previ-
ously described (25, 26), except that 3.5  105 TCIU HIV was mixed by
pipetting with either 5 l of vehicle (RPMI medium) or 8 l of whole
human breast milk prior to vaginal exposure. To assess the efficacy of a
topical application of breast milk on vaginal HIV transmission, 20 l of
breast milk was pipetted into the vagina of anesthetized BLT mice 15 min
prior to or 4 h before and after vaginal administration of virus. Intrave-
nous exposures of BLT mice to HIV were performed via tail vein injection
(200 l, total volume) following incubation of virus with whole human
breast milk (20 l, total volume) for 10 min at room temperature and
subsequent dilution with RPMI medium (1:10). As a positive control for
HIV infection, BLT mice were also exposed intravenously to HIV resus-
pended in 200 l of RPMI medium.
Human and nonhuman milk. We utilized whole breast milk obtained
from HIV-positive women enrolled in the Zambian Exclusive Breastfeed-
ing (ZEB) study at 1 month postpartum to evaluate the in vivo HIV-
inhibitory of breast milk from HIV-positive nontransmitting and trans-
mitting mothers. Details of the ZEB study are described elsewhere (28).
Briefly, HIV-infected women were recruited from two antenatal care clin-
ics in Lusaka, Zambia, from May 2001 to September 2004 and were mon-
itored through delivery and up to 2 years postpartum with their infants.
Single-dose nevirapine was administered to women at the onset of labor as
prophylaxis to prevent mother-to-child transmission. The study was ap-
proved by the investigators’ institutional review boards, and all women
consented in writing to participate in the study. All women were coun-
seled to exclusively breastfeed for the first 4 months or longer. HIV infec-
tion of infants was monitored in peripheral blood by PCR at birth,
monthly to 6 months of age, and then every 3 months thereafter until 2
years of age. All positive tests were confirmed by testing two or more
samples. HIV infection of infants was considered to have occurred
through breastfeeding if the infant first tested positive by PCR after 42
days of birth with an earlier negative result.
Whole breast milk was obtained from HIV-negative women (Innova-
tive Research, Novi, MI) to evaluate the HIV-inhibitory activity of heat-
inactivated, skim, and proteinase K-treated breast milk and to assess the
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effect of breast milk on vaginal and intravenous HIV acquisition. Whole
breast milk was heat inactivated for 30 min in a 62.5°C water bath (with
agitation every 10 min) and subsequently cooled in an ice bath prior to
exposure. The skim fraction of breast milk was isolated after centrifuga-
tion (1,000  g for 10 min) and aspiration of the lipid layer. Breast milk
was incubated with active or inactivated (incubated 90°C for 20 min)
proteinase K (Roche, Indianapolis, IN) at 50 g/ml at 55°C for 1 h, fol-
lowed by 90°C for 20 min. Untreated whole breast milk and whole breast
milk treated with active or inactive proteinase K was loaded onto a sodium
dodecyl sulfate (SDS)–10% polyacrylamide gel, followed by Coomassie
blue staining to visualize proteins.
Whole rhesus macaque (Macaca mulatta) milk was collected at 1
month postpartum from animals housed at the California National Pri-
mate Research Center according to protocols approved by the Institu-
tional Animal Care and Use Committee during an ongoing study. Whole
African green monkey milk (pooled from five donors) was collected from
animals housed and maintained by the Duke University Medical Center
Division of Laboratory Animal Resources Vivarium as a part of an ongo-
ing study according to protocols approved by the Institutional Animal
Care and Use Committee. Whole camel milk (pooled from six donors)
was obtained from the Camel Milk Association (Marion, MI). Human
milk oligosaccharides (HMOs) were isolated and purified from the milk
of 36 HIV-negative women as previously described (29). Briefly, after
removal of the lipid layer of breast milk by centrifugation, proteins were
precipitated from the aqueous phase of breast milk by the addition of
ice-cold ethanol and subsequent centrifugation. Ethanol was removed
from the HMO-containing supernatant by roto-evaporation, and lactose
and salts were removed by gel filtration chromatography. The milk was
donated to the Bode laboratory at the University of California, San Diego,
after approval by the university’s institutional review board. Breast milk
from HIV-negative women was enriched for TNC, a high-molecular-
weight protein, by high-pressure liquid chromatography (HPLC) high-
molecular-weight protein fractionation. Briefly, breast milk was delip-
idized by centrifugation at 4°C. Proteins in the aqueous fraction were
fractionated by size exclusion using a Superose 6 column (GE Healthcare,
Pittsburgh, PA) on an HPLC apparatus (Waters, Milford, MA). The high-
molecular-weight fractions were concentrated using Amicon 30K filter
columns (EMD Millipore, Billerica, MA) following strong anion ex-
change by HPLC. TNC was quantified in the high-molecular-weight
breast milk fractions using a TNC enzyme-linked immunosorbent assay,
and purity was determined by SDS-PAGE and Western blot analysis (30).
The TNC-enriched high-molecular-weight fractions of breast milk were
utilized for oral HIV challenges.
Analysis of HIV transmission in humanized BLT mice. HIV trans-
mission was determined by the presence of viral RNA in plasma (viral load
analysis) essentially as we have previously described (25, 26). The presence
of HIV DNA in tissues and peripheral blood cells collected from BLT mice
at necropsy was determined by real-time PCR analysis of DNA extracted
from mononuclear cells as previously described (25, 26). As a control for
the presence of DNA extracted from human cells, all samples were tested
for the presence of human gamma globin DNA by real-time PCR.
Statistical analysis. Statistical analyses were performed in Prism, ver-
sion 5 (GraphPad, La Jolla, CA). We used a log-rank Mantel-Cox test to
compare the rates of transmission between groups of BLT mice after oral,
vaginal, and intravenous HIV exposure.
RESULTS
In vivo HIV-inhibitory activity of breast milk from HIV-posi-
tive transmitting and nontransmitting mothers. We utilized
BLT humanized mice to evaluate the in vivo HIV-inhibitory activ-
ity of breast milk obtained from HIV-positive mothers. BLT mice
were exposed to a single oral dose of HIV resuspended in whole
breast milk collected at 1 month postpartum from HIV-positive
mothers enrolled in the Zambian Exclusive Breastfeeding (ZEB)
study (28). We evaluated breast milk samples collected from four
mothers that did not transmit HIV to their infants (nontransmit-
ters) and four mothers that transmitted HIV to their infants
through breastfeeding (transmitters). Breastfeeding HIV trans-
mission was considered to have occurred in the ZEB study if the
infant first tested positive by PCR after 42 days of birth with an
earlier negative result. As a positive control for oral HIV transmis-
sion, BLT mice were exposed to HIV in vehicle. After oral HIV
exposure, we monitored levels of HIV-RNA longitudinally in
plasma with real-time PCR. HIV transmission was defined by the
presence or absence of detectable HIV-RNA in plasma. Lack of
HIV infection was confirmed at necropsy by the absence of detect-
able HIV-DNA in peripheral blood (PB) and tissues harvested
from BLT mice.
We observed 100% transmission in BLT mice exposed orally to
HIV in vehicle (Fig. 1 and see Table S1 in the supplemental mate-
rial). However, HIV transmission was significantly reduced in
BLT mice exposed orally to HIV resuspended in breast milk from
HIV-positive transmitters (P  0.0145; 2/8 mice infected) and
nontransmitters (P  0.0077; 2/8 mice infected) (Fig. 1 and see
Table S1 in the supplemental material). Furthermore, although we
readily detected HIV-DNA in the PB and tissues analyzed from
BLT mice exposed orally to HIV in vehicle, we did not detect any
HIV-DNA in the PB or tissues collected from aviremic BLT mice
exposed orally to HIV in breast milk of HIV-positive mothers (see
Table S1 in the supplemental material). Breast milk obtained from
HIV-positive transmitting and nontransmitting mothers were
equally likely to inhibit oral HIV transmission (P  0.9676). We
observed oral HIV transmission in the presence of breast milk
obtained from two transmitting and two nontransmitting moth-
ers (Fig. 1; see also Table S1 in the supplemental material). Se-
quencing of HIV-RNA isolated from the plasma of viremic mice
exposed to HIV in breast milk confirmed that the transmitting
virus was the input virus (HIV-1JR-CSF) and not maternal virus
that may be present in the breast milk samples. Overall, our results
demonstrate that breast milk of HIV-positive mothers can pre-
vent HIV infection in vivo and that the breast milk of HIV-positive
transmitting mothers does not possess less potent in vivo HIV-
inhibitory activity than the breast milk of HIV-positive nontrans-
mitting mothers.
Species specificity of HIV-inhibitory activity of milk. We de-
termined whether this HIV-inhibitory effect was specific to hu-
man breast milk by evaluating the protective features of the milk
of other taxa. Although mammalian milk primarily consists of
water, fats, proteins, and carbohydrates, across the mammalian
class, milk composition varies substantially as a function of phy-
logeny, nutritional ecology, and developmental priorities (31–37).
For this purpose, we obtained unpasteurized whole milk from
species that are closely related to humans (African green monkeys
[AGMs] and rhesus macaques [RMs]) and from more distantly
related species that are abundant sources of dietary milk (cow,
goat, and camel). To assess the in vivo HIV-inhibitory activity of
milk collected from these species, we exposed groups of BLT mice
orally to HIV resuspended in vehicle (positive control), cow, goat,
camel, RM, or AGM milk as we described for human breast milk
above except that we reduced the rate of oral HIV transmission to
better appreciate whether the milk of the species tested inhibits,
enhances, or has no effect on HIV transmission.
Our results revealed that oral transmission of HIV was not
significantly inhibited (or enhanced) by cow, goat, camel, RM, or
AGM milk (Fig. 2 and see Table S2 in the supplemental material).
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HIV-RNA was readily detected in the plasma of BLT mice exposed
orally to virus in vehicle (66% transmission) and nonhuman milk
(transmission rates: 75% cow milk, P  0.8784; 50% goat milk,
P  0.5522; 50% camel milk, P  0.5522; 50% RM milk, P 
0.4380; and 50% AGM milk, P  0.4380) (Fig. 2). These results are
in stark contrast to our studies with human breast milk in which
we observed significantly reduced oral HIV transmission in the
presence of breast milk from HIV-negative (24) (Fig. 2) and HIV-
positive (Fig. 1) women. Collectively, these results reveal that the
HIV-inhibitory activity of milk is species specific and that the
ability of human breast milk to inhibit HIV infection in vivo is not
due to a nonspecific inhibitory property of milk.
Nature of breast milk’s HIV-inhibitory activity. We charac-
terized the nature of breast milk’s HIV-inhibitory activity by eval-
uating the effect of heat-inactivation and lipid removal on breast
milk inhibition of HIV transmission. In addition, we evaluated the
in vivo HIV-inhibitory activity of individual breast milk compo-
nents that have been shown to inhibit HIV infection in vitro. Sev-
eral immune components of breast milk are significantly reduced
by Holder pasteurization (heating to 62.5°C for 30 min) (38).
Therefore, we exposed BLT mice orally to HIV resuspended in
heat-inactivated (62.5°C, 30 min) whole breast milk from HIV-
negative women. We observed that heat-inactivated breast milk
significantly reduced oral HIV transmission in BLT mice com-
pared to vehicle (P  0.0143; 0/4 mice infected) (Fig. 3A and see
Table S3 in the supplemental material). Heat-inactivated whole
breast milk inhibited oral HIV transmission as efficiently as un-
treated whole breast milk (24). After oral exposure, we did not
detect any HIV-RNA in the plasma of BLT mice exposed to virus
in heat-inactivated breast milk at any time point analyzed. Also, at
necropsy, we did not detect any HIV-DNA in their PB or tissues
(Fig. 3A and see Table S3 in the supplemental material). These
results reveal that the in vivo HIV-inhibitory activity of human
breast milk is not sensitive to heat inactivation.
Next, we determined if the skim fraction of human breast milk
is sufficient to inhibit oral transmission of HIV. The majority of
the 260 proteins and carbohydrates in breast milk reside in the
skim fraction (31). We isolated the skim fraction after centrifuging
whole breast milk from HIV-negative women (1,000  g for 10
min) and aspirating off the cream (lipid layer). In contrast to BLT
mice exposed orally to virus in vehicle, HIV-RNA was detected in
the plasma of only one animal exposed to virus in the presence of
skim breast milk (Fig. 3A and see Table S3 in the supplemental
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FIG 1 Breast milk of HIV-positive nontransmitting and transmitting mothers inhibits HIV infection in vivo. Groups of BLT mice were exposed orally to HIV
resuspended in breast milk (BM) obtained 1 month postpartum from HIV-positive nontransmitting (4 donors, 2 mice per donor) (A) and transmitting (4
donors, 2 mice per donor) (B) mothers. (C) As a positive control for oral HIV transmission, BLT mice were exposed to HIV in vehicle (n  5). After oral exposure,
HIV-RNA was measured longitudinally in plasma with real-time PCR, and the assay limit of detection is indicated with a dashed line (750 copies/ml of plasma).
The plasma viral load for each mouse is indicated. For panels A and B, data for BLT mice exposed to virus in the presence of BM from the same donor are depicted
by the same shape. (D) A Kaplan-Meier plot depicts the percentage of BLT mice in each exposure group that did not become infected with HIV. HIV transmission
was defined by the presence of HIV-RNA in plasma. A log-rank Mantel-Cox test was used to compare HIV transmission between BLT mice exposed orally to HIV
in vehicle and in BM (P values are indicated).
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mission in vivo (P  0.0452; 1/5 mice infected). Furthermore,
real-time PCR analysis did not reveal any HIV-DNA in the PB or
tissues of BLT mice that did not have detectable viremia, confirm-
ing a complete lack of infection (see Table S3 in the supplemental
material).
Next, we proceeded to evaluate the contribution of milk pro-
teins to breast milk’s in vivo HIV-inhibitory activity. First, we
evaluated the in vivo HIV-inhibitory activity of individual breast
milk proteins that have been shown to inhibit HIV infection in
vitro. To evaluate the in vivo HIV-inhibitory activity of TNC, we
exposed BLT mice orally to HIV in vehicle or vehicle supple-
mented with TNC-enriched breast milk (78 to 168 g of TNC/
ml). Subsequently, we observed HIV-RNA in the plasma of 7 of 8
BLT mice (87% transmission) exposed orally to HIV in the pres-
ence of TNC (Fig. 3B). These results indicate that TNC does not
inhibit oral HIV transmission at physiological concentrations
(P  0.7075). We also observed that breast milk purified lactofer-
rin (LF), a well-characterized component of breast milk that has
been shown to inhibit HIV infection in vitro, does not inhibit oral
HIV transmission in BLT mice at maximal concentrations (7 mg/
ml) observed in human colostrum (39) (4/4 mice infected; P 
0.1088) (Fig. 3B).
To further establish the role of milk proteins in breast milk
inhibition in vivo, we then treated whole breast milk with 50 g of
active or inactive proteinase K (PK)/ml. Proteolytic digestion of
breast milk proteins by PK was confirmed by SDS-PAGE and
Coomassie blue staining (see Fig. S1 in the supplemental mate-
rial). Oral exposure of BLT mice to HIV resuspended in breast
milk treated with active PK and inactive PK revealed that proteo-
lytic digestion of breast milk proteins does not significantly alter
the ability of breast milk to inhibit HIV infection in vivo. We did
not detect HIV-RNA in the plasma of 8/9 BLT mice exposed orally
to HIV in the presence of breast milk treated with active PK (P 
0.001) and 6/7 BLT mice orally exposed to HIV in breast milk
treated with inactive PK (P  0.0034). In addition, we did not
detect HIV-DNA in the tissues of plasma viremia negative animals
(Fig. 3C and see Table S4 in the supplemental material). Collec-
tively, these results indicate the in vivo HIV-inhibitory activity of
milk is not protein dependent.
We then proceeded to evaluate the ability of human milk oli-
gosaccharides (HMOs) to inhibit HIV infection in vivo. Increased
concentrations of HMOs in breast milk have been associated with
decreased HIV transmission during breastfeeding (11). In addi-
tion, in comparison to the milks of the other species evaluated
here, including RM, the oligosaccharides present in human breast
milk are more abundant and diverse (32, 36, 40, 41). Furthermore,
HMOs are not affected by Holder pasteurization and are present
in the skim fraction of breast milk (38). HMOs could potentially
reduce HIV transmission by inhibiting DC-SIGN mediated trans-
fer of HIV from dendritic cells to CD4 T cells (42). To evaluate
the effect of HMOs on oral HIV transmission, we orally exposed
BLT mice to HIV in vehicle supplemented with 20 mg/ml HMOs
(the average concentration of HMOs present in human colos-
trum) (36) purified from the breast milk of HIV-negative women
(29). Surprisingly, we observed 75% transmission in BLT mice
exposed orally to HIV in the presence of HMOs (3/4 mice in-
fected) (Fig. 3D). These results indicate that although increased
concentrations of HMOs in breast milk are correlated with de-
creased breastfeeding HIV transmission, HMOs alone do not in-
hibit oral HIV transmission. Altogether, these results suggest that
that multiple components of breast milk (i.e., lipids, proteins,
and/or carbohydrates) likely work in concert to inhibit oral HIV
transmission during breastfeeding.
Effect of breast milk on other modes of HIV acquisition. In
the future, the HIV-inhibitory factors in breast milk or molecules
that mimic their activity could potentially be used to prevent other
routes of HIV acquisition. Therefore, we determined if breast milk
could inhibit other modes of HIV infection in vivo or if the inhib-
itory effect of breast milk is specific to oral transmission.
Previously, we demonstrated that the female reproductive tract
of BLT mice is reconstituted with human target cells for HIV
infection (CD4 T cells, dendritic cells, and macrophages), ren-
dering them susceptible to vaginal HIV transmission (25, 27). In
addition, we previously validated BLT mice for the in vivo evalu-
ation of topical HIV preventive strategies (25, 26). Therefore, we
used BLT mice to determine whether human breast milk can in-
hibit vaginal transmission of HIV, the most relevant mucosal
route of HIV acquisition globally (5).
First, we confirmed the susceptibility of BLT mice to HIV
transmission following a single vaginal exposure to HIV in vehicle.
Transmission was monitored in plasma as described above. Under
these conditions, we observed 100% transmission (5/5 mice in-
fected) (Fig. 4 and see Table S5 in the supplemental material).
Importantly, when we exposed BLT mice vaginally to HIV mixed
with human breast milk immediately prior to exposure, no mouse
became infected (0/4 mice infected), as determined by the absence
Vehicle (n=9 mice)
Cow  (n=4 mice): p=0.7167RM (n=8 mice): p=0.5300
Goat (n=4 mice): p=0.6204
Camel (n=4 mice): p=0.6204
























100 Human Breast Milk
FIG 2 The milk of other species does not inhibit HIV transmission. BLT mice
were exposed orally to HIV in the presence of cow (n  4, light blue line), goat
(n  4, green line), camel (n  4, purple line), rhesus macaque (RM), (n  8,
blue line), or African green monkey (AGM) (n  4, brown line) milk. As a
positive control, BLT mice were exposed orally to HIV in vehicle (n  11, red
line). Infection was monitored longitudinally in plasma with real-time PCR.
HIV transmission was defined by the presence of HIV-RNA in plasma. A
Kaplan-Meier plot depicts the percentage of BLT mice in each exposure group
that did not become infected with HIV. Oral HIV transmission in the presence
of human breast milk (BM) from HIV-negative women (5 donors; n  18
mice) is illustrated with a dashed black line (24). A log-rank Mantel-Cox test
was used to compare HIV transmission between BLT mice exposed orally to
HIV in vehicle and in milk (P values are indicated).
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of HIV-RNA in the plasma of any mouse at any time point post-
exposure (Fig. 4). Lack of HIV transmission was confirmed at
necropsy by the absence of HIV-DNA in PB and harvested tissues
(see Table S5 in the supplemental material). These results demon-
strate that breast milk can prevent vaginal HIV transmission, the
most common mode of mucosal HIV acquisition, when virus is
mixed with human breast milk (P  0.0081).
Having demonstrated that human breast milk can prevent vag-
inal infection, we proceeded to determine whether breast milk can
inhibit vaginal HIV transmission when it is applied directly into
the vagina prior to exposure, mimicking topical application of a
microbicide. When we applied breast milk topically to the vagina
15 min prior to vaginal HIV exposure, we observed a significant
reduction in transmission (P  0.0086; 2/6 mice infected) (Fig. 4
and see Table S5 in the supplemental material). CAPRISA004, the
first successful clinical microbicide trial in humans, demonstrated
a significant reduction in vaginal HIV transmission when the mi-
crobicide tenofovir was applied vaginally once before and once
after sexual intercourse within a 24-h period (43). Previously, we
also demonstrated that topical application of a 1% tenofovir gel,
administered up to 12 h before and within 12 h after vaginal HIV
exposure, dramatically reduced HIV transmission in BLT mice
(1/8 mice infected) (15). Therefore, we next assessed the effect of
two topical applications of breast milk, administered once before
and once after vaginal HIV exposure, on vaginal HIV transmis-
sion. When breast milk was applied topically 4 h before and after
vaginal HIV exposure, we observed a 50% reduction in vaginal
HIV transmission (P  0.1332; 2/4 mice infected) (Fig. 4 and see
Table S5 in the supplemental material). Lack of vaginal HIV trans-
mission was confirmed in BLT mice that received breast milk top-
ically at necropsy by the absence of HIV-DNA in PB and tissues
(see Table S5 in the supplemental material). Collectively, these
results indicate that breast milk can significantly reduce vaginal
HIV transmission when virus is mixed with breast milk or when
breast milk is applied topically immediately prior to exposure
(Fig. 4).
The fact that breast milk is not as effective at preventing vaginal
HIV transmission when it is applied topically 4 h before and after
exposure suggests that inhibitory factors in breast milk may act
directly on the virus to prevent mucosal transmission. Therefore,
we next wanted to determine whether breast milk can prevent
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FIG 3 Nature of breast milk’s HIV-inhibitory activity. (A) BLT mice were exposed orally to HIV in the presence of heat-inactivated whole breast milk (BM)
(n  4), the skim fraction of BM (n  5), or vehicle (n  6, positive control). (B) BLT mice were orally exposed to HIV in vehicle (n  6, positive control) or in
vehicle supplemented with tenascin-C (78 to 168 g/ml)-enriched BM (n  8) or lactoferrin (7 mg/ml; n  4). (C) BLT mice were exposed orally to HIV in
vehicle (n  5, positive control) or in the presence of BM treated with active (n  9) or inactive (n  7) proteinase K. HIV infection was monitored longitudinally
in plasma with real-time PCR. Kaplan-Meier plots depict the percentage of BLT mice in each exposure group that did not become infected with HIV. HIV
infection was defined by the presence of HIV-RNA in plasma. A log-rank Mantel-Cox test (P values are indicated) was used to compare HIV transmission
between BLT mice exposed orally to virus in vehicle and in BM. (D) BLT mice (n  4) were exposed orally to vehicle supplemented with human milk
oligosaccharides (20 mg/ml). HIV infection was monitored longitudinally in plasma with real-time PCR; the limit of detection is indicated with a dashed line.
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intravenous injection (bypassing the mucosa). HIV is most effec-
tively transmitted in humans following an intravenous exposure.
For this purpose, we incubated HIV with whole breast milk for 10
min then diluted the virus-breast milk mixture with vehicle (1:10)
prior to intravenous injection into BLT mice. BLT mice exposed
intravenously to HIV in vehicle served as a positive control for
HIV infection. Surprisingly, while we readily detected HIV-RNA
in the plasma of all BLT mice exposed intravenously to HIV in
vehicle at 1 week postexposure (6/6 mice infected), we did not
detect any HIV-RNA in the plasma of any BLT mouse injected
intravenously with HIV pretreated with breast milk at any time
point postexposure (0/3 mice infected) (Fig. 5 and see Table S6 in
the supplemental material). In addition, at necropsy (11 to 12
weeks postexposure), we did not detect any HIV-DNA in the PB
or tissues of BLT mice exposed intravenously to HIV pretreated
with breast milk (see Table S6 in the supplemental material).
However, when we increased the dose of virus pretreated with
breast milk 15-fold and intravenously injected BLT mice, we ob-
served increased HIV infection (2/3 mice infected) (Fig. 5 and see
Table S6 in the supplemental material). These results suggest that
HIV-inhibitory factor(s) in breast milk may act directly on the
virus and that this activity can be saturated by increased amounts
of virus.
DISCUSSION
Although up to one-half of HIV infections in children can be
attributed to breastfeeding, only a small percentage of infants
(15%) breastfed by HIV-positive women become infected with
HIV despite daily exposure to virus in breast milk for several
months to years (44). Previously, our laboratory and others dem-
onstrated that the low risk of acquiring HIV during breastfeeding
(0.00028 per day of breastfeeding) (45) is likely due to the innate
HIV-inhibitory activity of breast milk; the breast milk of HIV-
negative women, which contains no HIV-specific antibodies or
immune cells, can inhibit HIV infection in cell culture and prevent
oral HIV transmission in vivo (24, 46–48). Here, we demonstrated
that breast milk of HIV-positive mothers (transmitters and non-
transmitters) significantly inhibits HIV transmission. We also
demonstrated that breast milk can prevent multiple routes of HIV
acquisition and that this activity is unique to human milk. In
addition, our results indicate that breast milk possesses multiple
factors that contribute to breast milk inhibition of HIV.
The ability of breast milk obtained from HIV-negative women
to inhibit HIV infection in vitro and in vivo has been established;
however, to our knowledge, the HIV-inhibitory activity of breast
milk obtained from HIV-positive women had not been evaluated.
In addition, although differences in breast milk composition be-
tween transmitting and nontransmitting HIV-positive mothers
have been correlated with an increased risk for breastfeeding HIV
transmission, it is not known if changes in the composition of
breast milk alters its in vivo HIV-inhibitory activity. This informa-
tion could be critical for the design of novel approaches to prevent
HIV transmission through breastfeeding that do not deny infants
in resource-limited settings the health benefits of breast milk.
Therefore, we evaluated the ability of breast milk obtained from
HIV-positive transmitting and nontransmitting mothers to in-
hibit oral HIV transmission in BLT mice. Our results revealed that
breast milk of HIV-positive mothers can significantly inhibit HIV
infection in vivo. These results are consistent with the observation
that most infants breastfed by HIV-positive women do not ac-
quire HIV during breastfeeding.
Our data also revealed no significant difference in the in vivo
HIV-inhibitory activity of breast milk obtained from HIV-posi-
tive nontransmitting and transmitting mothers. The breast milk
samples evaluated in our study were obtained from HIV-positive
mothers at 1 month postpartum. It is highly unlikely that our

























BM at Exposure (n=4 mice): p=0.0081
Topical BM 15 min Pre-Exposure (n=6 mice): p=0.0086
Topical BM 4 h Pre/Post-Exposure (n=4 mice): p=0.1332
Vehicle (n=5 mice)
FIG 4 Human breast milk can inhibit vaginal HIV transmission. The inhibi-
tory effect of breast milk on vaginal HIV transmission was examined by expos-
ing groups of BLT mice vaginally to HIV in vehicle (n  5, positive control) or
breast milk (n  4). The effect of topically applied breast milk (BM) adminis-
tered to BLT mice 15 min prior to exposure (n  6) or 4 h pre- and postexpo-
sure (n  4) on vaginal HIV transmission is shown. Infection was monitored
in plasma by measuring viral load. A Kaplan-Meier plot depicts the percentage
of BLT mice in each exposure group that did not become infected with HIV
following vaginal HIV exposure in the presence or absence of BM (as deter-
mined by the absence of HIV-RNA in plasma). A log-rank Mantel-Cox test (P
values are indicated) was used to compare HIV transmission between BLT
mice that were exposed vaginally to HIV in vehicle (no BM) to those that
received HIV vaginally in BM (BM at exposure) or in vehicle following topical


























BM: 1.4 x 106 TCIU HIV-1JR-CSF (n=3 mice): p=0.1573
BM: 9 x 104 TCIU HIV-1JR-CSF (n=3 mice): p=0.0047
Vehicle: 9 x 104 TCIU HIV-1JR-CSF (n=6 mice)
FIG 5 Human breast milk prevents intravenous HIV infection. BLT mice
were exposed intravenously to 9  104 TCIU HIV mixed with breast milk
(BM) (n  3) or vehicle (n  6, positive control) for 10 min prior to exposure.
BLT mice (n  3) were also exposed to a high intravenous dose of HIV (1.4 
106 TCIU) pretreated with BM. A Kaplan-Meier plot depicts the percentage of
BLT mice in each group that did not become infected following intravenous
exposure to HIV in the presence or absence of BM. HIV infection was defined
by the presence of HIV-RNA in plasma. A log-rank Mantel-Cox test (P values
are indicated) was used to compare HIV transmission between BLT mice ex-
posed intravenous to HIV in whole BM versus vehicle.
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level of nevirapine in breast milk falls below the limit of detection
by 17 days postadministration (49). One explanation for our re-
sult is that HIV transmission in the presence of breast milk is
influenced by transient changes in breast milk composition. The
composition of breast milk, including the concentration of previ-
ously characterized anti-HIV factors in breast milk, changes dur-
ing lactation (50, 51). In addition, while the risk of transmission
remains throughout the lactation period, early lactation and
weaning are associated with an increased risk of transmission. In
the future, it will be important to evaluate the in vivo HIV-inhib-
itory activity of breast milk obtained from HIV-positive mothers
at multiple time points postpartum. Another potential explana-
tion for our observation is that cell-associated HIV is transmitted
more frequently than cell-free HIV and is less susceptible to breast
milk inhibition, especially at earlier stages of lactation. Longitudi-
nal analyses of cell-free and cell-associated viral loads in breast
milk of HIV-positive nontransmitting and transmitting mothers
indicated that the level of cell-associated HIV in breast milk was
predictive of breastfeeding transmission during early lactation
(52, 53). Further in vivo analysis comparing the ability of breast
milk from HIV-positive mothers to inhibit oral transmission of
cell-free and cell-associated HIV transmission will be needed to
address this issue. Breastfeeding HIV transmission has been cor-
related with viral, maternal, and infant risk factors (54). Viral
characteristics associated with breastfeeding HIV transmission in-
clude: replicative fitness, the length of the variable loop, number of
N-linked glycosylation sites in Env, and subtype (55–58). In the
future, it will be important to determine if breast milk inhibits all
virus isolates equally, and, in particular, as they become available,
transmitted/founder viruses that were acquired via breastfeeding.
It should also be noted that mice do not have tonsils, a potential
site of HIV transmission following an oral exposure. The presence
of human HIV target cells has been demonstrated in the nasal-
associated lymphoid tissue, the functional equivalent of tonsils, in
BLT mice (24).
Defining the mechanism by which breast milk inhibits HIV
infection in vivo will aid the development of novel approaches
to prevent HIV transmission. Although several components of
breast milk have been shown to inhibit HIV infection in vitro, their
contribution to breast milk inhibition in vivo has not been exam-
ined. Collectively, our data indicate that the in vivo HIV-inhibi-
tory activity of milk is specific to humans and that multiple factors
in breast milk may act to collectively inhibit oral HIV transmis-
sion.
We defined the species specificity of milk’s in vivo HIV-inhib-
itory activity by evaluating oral HIV transmission in the presence
of whole milk obtained from species that are closely related to
humans (AGMs and RMs) and from species that are distantly
related to humans but are more abundant sources of milk (cows,
goats, and camels). Although the composition of AGM milk has
not been well studied, the composition of RM milk closely resem-
bles that of human breast milk, in comparison to the milk of the
other species tested (cows, goats, and camels). More importantly,
RM milk possesses several of the innate factors, and at concentra-
tions similar or slightly reduced to those observed in human breast
milk, that have been reported to either inhibit HIV in vitro (i.e., LF
and lysozyme) or are associated with a decreased risk for HIV
transmission (i.e., LCPUFAs) (59–61). Despite these similarities,
we observed no significant decrease in HIV transmission when we
exposed BLT mice orally to HIV in the presence of RM milk (50%
transmission in RM milk versus 66% transmission in vehicle). We
also observed no significant decrease in oral HIV transmission
when mice were exposed to virus in AGM, cow, goat, or camel
milk. Interestingly, while breastfeeding SIV transmission has been
documented in RMs, AGMs rarely transmit SIV postnatal (62,
63). Although we did not evaluate the ability of AGM and RM milk
to inhibit SIV infection, our data suggest that the lack of postnatal
SIV transmission in AGMs is likely not due to differences in milk
composition between the two nonhuman primates. Taken to-
gether, our results indicate that the in vivo HIV-inhibitory activity
of milk is specific to humans and that the ability of breast milk to
inhibit HIV transmission is not due to a nonspecific property of
milk.
To aid the identification of the factor(s) in breast milk that
inhibit HIV infection in vivo, we performed a series of experi-
ments to better understand the nature of breast milk’s in vivo
HIV-inhibitory activity. Our results demonstrating the potent
ability of heat-inactivated breast milk and the skim breast milk to
inhibit oral HIV transmission suggested that the inhibitory fac-
tor(s) in breast milk may be a heat-stable protein or carbohydrate.
To examine the contribution of milk proteins to breast milk’s in
vivo HIV-inhibitory activity, we exposed BLT mice orally to HIV
resuspended in proteinase K-treated breast milk. Surprisingly, we
observed decreased oral HIV transmission in the presence of pro-
teinase K-treated breast milk, indicating that breast milk proteins
are not essential for breast milk inhibition of HIV infection in vivo.
Our results also demonstrated that the previously characterized
anti-HIV breast milk proteins TNC and LF were not able to sig-
nificantly inhibit HIV infection in vivo when evaluated individu-
ally at physiologic concentrations. These data indicate that while
breast milk factors may display HIV-inhibitory activity in vitro,
they may not be potent enough at physiological concentrations in
breast milk to significantly inhibit HIV infection in vivo. We then
proceeded to determine whether HMOs isolated from the breast
milk of HIV-negative women can inhibit oral HIV transmission.
While increased concentrations of HMOs in breast milk are cor-
related with a decreased risk for HIV transmission during breast-
feeding (5), the results of our study indicate that bulk HMOs do
not inhibit HIV infection in vivo. We observed no significant de-
crease in HIV transmission when we exposed BLT mice orally to
HIV in vehicle containing a high concentration of purified HMOs.
Increased concentrations of non-3=-sialylated HMOs have also
been associated with a decreased breastfeeding transmission. In
the future it may be important to evaluate the efficacy of non-3=-
sialylated HMOs alone to inhibit oral HIV transmission. Although
we did not evaluate the ability of the lipid fraction to inhibit oral
HIV transmission, it is possible that lipids contribute to breast
milk’s in vivo HIV-inhibitory activity, given that this activity was
retained after proteolytic digest of milk proteins. The observation
that the in vivo anti-HIV activity of breast milk is maintained in
the skim fraction of milk and after heat-inactivation and proteo-
lytic digest of milk indicates that there is redundancy in breast
milk’s in vivo HIV-inhibitory activity. Altogether, our data suggest
that breast milk contains multiple factors (lipids, proteins, and/or
carbohydrates) that together inhibit oral HIV transmission and
suggest that breast milk can inhibit HIV transmission even if the
concentration of one or more anti-HIV factors in breast milk is
reduced. In addition, the HIV-inhibitory activity of breast milk of
HIV-positive mothers may be further enhanced by the presence of
HIV-specific antibodies and immune cells.
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HIV is most frequently transmitted vaginally to women who
live in resource-limited settings, such as sub-Saharan Africa, and
lack access to acceptable and/or affordable prophylaxis, such as
condoms and microbicides (64). In the absence of an effective
vaccine that provides protection from HIV infection, there is an
urgent need to develop and implement novel prevention strate-
gies. Non-ART-based prevention modalities have been evaluated
in humans in the past. However, none were efficacious and in
some instances they increased transmission (65). Our laboratory
and others have shown that human breast milk has a strong inhib-
itory effect on HIV infection in vitro and in vivo. Therefore, we
hypothesized that breast milk could also prevent other modes of
mucosal HIV transmission. Our data reveal that whole human
breast milk can significantly inhibit vaginal HIV transmission
when breast milk is mixed with virus before exposure and when it
is applied topically to the vagina 15 min prior to exposure. Al-
though we did not observe statistically significant protection when
breast milk was applied topically 4 h before and after vaginal HIV
exposure, HIV transmission was reduced by 50%. In comparison,
during CAPRISA004, HIV transmission was reduced by 39%
when a 1% tenofovir gel was applied topically up to 12 h before
and after vaginal HIV exposure (43). Collectively, our results sug-
gest that the anti-HIV factors in milk or molecules that mimic
their activity have the potential for use as a microbicide compo-
nent. We did observe that the protective effect of breast milk on
vaginal HIV transmission decreased when breast milk was applied
topically prior to exposure in comparison to vaginal exposures
performed with virus resuspended in breast milk. In addition,
vaginal transmission was increased as the time between the vaginal
exposure and the topical application of breast milk increased.
These results suggest that the protective factors in breast milk may
act directly on the virus and not the target cell. Indeed, we ob-
served 100% protection when we bypassed the mucosa and ex-
posed BLT mice intravenously to HIV pretreated with breast milk
for 10 min. However, the protective effect of breast milk could be
saturated by increasing the intravenous HIV inoculum 15-fold.
Overall, the results of our experiments indicate that breast milk
contains powerful in vivo HIV-inhibitory activity that can prevent
multiple routes of HIV acquisition. Our data here suggest that the
HIV-inhibitory activity of breast milk may be attributed to mul-
tiple factors that act directly on the virus. Regardless of their po-
tential use as topical HIV preventatives, identification of the sub-
stances present in milk capable of inhibiting mucosal HIV
transmission may aid the development of novel approaches to
prevent mother-to-child transmission. Natural approaches to
prevent vertical or horizontal HIV transmission might be espe-
cially useful in resource-limited settings where they are most
needed.
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